In preclinical and phase 1 ... who had treatment-resistant hypertension, with blood pressure of 130/80 mm Hg or higher, and who were receiving stable doses of at least three antihypertensive ...

8-10 In the phase 2 PULSAR trial, which involved 106 patients receiving background therapy for pulmonary arterial hypertension, 24 weeks of treatment ... to its role in the design of the trial ...

The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ... including benefits in both progression-free and overall survival in frontline treatment, and we continue to observe strong ...

No new safety findings have been observed with continued blarcamesine treatment over three (3) years with good ... Investigator for the blarcamesine Phase IIb/III ANAVEX ® 2-73-AD-004 study.

Aura Biosciences announced that it has received an agreement from the FDA under a special protocol assessment for the design of a phase 3 trial ... for bel-sar for the treatment of early-stage ...

Recovery was more likely for people treated with conformal, or highly targeted, radiation techniques, compared to standard whole-brain treatment ... in three large, randomized phase III clinical ...